AbCellera Biologics (ABCL) Total Liabilities (2020 - 2026)

AbCellera Biologics' Total Liabilities history runs 7 years deep, the most recent figure standing at $369.0 million for Q1 2026.

• Quarterly Total Liabilities rose 14.88% year-over-year to $369.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $369.0 million (up 14.88% YoY) and the FY2025 annual result came in at $390.0 million, up 28.11% from the prior year.
• Total Liabilities was $369.0 million for Q1 2026 at AbCellera Biologics, down from $390.0 million in the prior quarter.
• Across five years, Total Liabilities topped out at $395.0 million in Q2 2025 and bottomed at $289.4 million in Q1 2023.
• A 5-year average of $340.8 million and a median of $333.2 million in 2024 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities jumped 124.49% — and 2023, when it dropped 24.78%.
• AbCellera Biologics' Total Liabilities stood at $307.6 million in 2022, then grew by 9.15% to $335.8 million in 2023, then dropped by 9.32% to $304.5 million in 2024, then rose by 28.11% to $390.0 million in 2025, then fell by 5.39% to $369.0 million in 2026.
• Business Quant data shows ABCL's Total Liabilities at $369.0 million in Q1 2026, $390.0 million in Q4 2025, and $392.0 million in Q3 2025.